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ABSTRACT
The IUPHAR/BPS Guide to PHARMACOLOGY
(GtoPdb, www.guidetopharmacology.org) and its
precursor IUPHAR-DB, have captured expert-curated
interactions between targets and ligands from se-
lected papers in pharmacology and drug discov-
ery since 2003. This resource continues to be de-
veloped in conjunction with the International Union
of Basic and Clinical Pharmacology (IUPHAR) and
the British Pharmacological Society (BPS). As pre-
viously described, our unique model of content se-
lection and quality control is based on 96 target-
class subcommittees comprising 512 scientists col-
laborating with in-house curators. This update de-
scribes content expansion, new features and in-
teroperability improvements introduced in the 10
releases since August 2015. Our relationship ma-
trix now describes ∼9000 ligands, ∼15 000 bind-
ing constants, ∼6000 papers and ∼1700 human
proteins. As an important addition, we also in-
troduce our newly funded project for the Guide
to IMMUNOPHARMACOLOGY (GtoImmuPdb, www.
guidetoimmunopharmacology.org). This has been
‘forked’ from the well-established GtoPdb data model
and expanded into new types of data related to the
immune system and inflammatory processes. This
includes new ligands, targets, pathways, cell types
and diseases for which we are recruiting new IUPHAR
expert committees. Designed as an immunopharma-
cological gateway, it also has an emphasis on poten-
tial therapeutic interventions.
INTRODUCTION
The International Union of Basic and Clinical
Pharmacology/British Pharmacological Society
IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb,
www.guidetopharmacology.org) is an expert-curated re-
source of ligand–activity–target relationships, selected
from high-quality pharmacological and medicinal chem-
istry literature. It has its origins in IUPHAR-DB, first
compiled in 2003 and focused on receptors and channels
(1–3). From 2012 to 2015, the scope expanded to define the
data-supported druggable genome and the resource was
re-named GtoPdb (4,5). This phase added many new target
families and consolidated ligand-to-target relationships
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for approved drugs and clinical candidates. Over the last
2 years, under the guidance of the IUPHAR Committee
on Receptor Nomenclature and Drug Classification (NC-
IUPHAR) and its 96 expanded subcommittees (comprising
512 international scientists), we have added quantitative
ligand–target relationships showing promise for future
drug discovery. We have also enhanced interoperability
with other resources and added features to help users access
structure-activity relationship (SAR) data and to explore
species differences using a new ligand activity visualization
tool.
From 2015, we have addressed the priority area of im-
munity, inflammation and infection (6–9). Most chronic
diseases, including ageing, have an immune-inflammatory
component (10); auto-immunity is a serious problem
(11,12), and the progress of infections depends on im-
mune and inflammatory responses (13). There is also in-
creased interest in anti-tumour immune activity, the impor-
tance of which is underlined by a new partnership between
IUPHAR and the International Union of Immunological
Sciences (IUIS) to create standard tools and nomenclature.
Critical to facilitate this is a strong connection between
the immunity, inflammation and infection research and the
pharmacological communities, with easy bidirectional data
flow. In particular, pharmacological information is difficult
for immunologists to access without chemoinformatic ex-
pertise not typically present in immunology labs. Immunol-
ogy is supported by excellent databases––e.g. ImmPort
(www.immport.org), ImmGen (www.immgen.org), Innat-
eDB (www.innatedb.ca/), Reactome (www.reactome.org)
and IMGT (www.imgt.org)––but these do not provide easy
links to pharmacological data. The development of the
‘IUPHAR Guide to IMMUNOPHARMACOLOGY’ (or
GtoImmuPdb for short), with an immunologist-friendly
portal, aims to address this gap in information exchange.
All data added for the immunopharmacology project are
also available from the original GtoPdb site and vice versa.
GUIDE TO PHARMACOLOGY CURATION AND EX-
PANSION
The value of the database arises from our approach to doc-
ument selection, data curation and annotation. Our cura-
tion ‘rules’ are better seen as flexible guidelines because
expert judgement is exercised at all stages of the process,
with the overriding pragmatic principle being to expand
content value while maintaining stringency. This quality-
centric, ‘small data’ approach contrasts with automated
data-mining, large-scale curation operations and ‘big data’
amalgamation efforts. Curation includes checking and fix-
ing author errors (e.g. M versus nM), adding PubChem
cross-pointers between unresolved stereoisomers to the ap-
propriate stable R and S forms, and splitting salts and
parents for cheminformatic consistency while also cross-
pointing to reported salt forms (e.g. specified by the United
States Adopted Names (USAN) or Food and Drug Ad-
ministration (FDA) drug information sheet). We have re-
cently simplified the representation of activity ranges to
one-value-one-reference relationships, extending this prin-
ciple for patent-only entries and adapting legacy data to this
form.
Content
Targets. A ‘target’ record in our database resolves to a
UniProtKB/SwissProt Accession as its primary identifier.
Since our 2016 publication (5), target expansion has been
mainly for GtoImmuPdb. Specifically-added immunity, in-
flammation and infection targets include the following the
pattern recognition receptors/proteins of the innate im-
mune response:
RIG-I-like receptor family (www.guidetopharmacology.
org/GRAC/FamilyDisplayForward?familyId=940)
Absent in melanoma-like receptors
(www.guidetopharmacology.org/GRAC/
FamilyDisplayForward?familyId=942)
C-type lectin-like receptors (www.guidetopharmacology.
org/GRAC/FamilyDisplayForward?familyId=945)
Other pattern recognition receptors (www.
guidetoimmunopharmacology.org/GRAC/
FamilyDisplayForward?familyId=929)
Immune checkpoint protein targets have been expanded
and aggregated in new families, for example Immune check-
point catalytic receptors (www.guidetopharmacology.org/
GRAC/FamilyDisplayForward?familyId=953) and ‘Other
immune checkpoint proteins’ (www.guidetopharmacology.
org/GRAC/FamilyDisplayForward?familyId=949). This
allows us to capture the action of these proteins as both
immune system regulators and as drug targets. Another
new target family is Butyrophilin and butyrophilin-like
proteins were added for their increasingly indicated roles
in gamma-delta T cells (14). As part of our ongoing
updates of the GtoPdb, we have added other, non-immune
targets, including the aryl hydrocarbon receptor and Piezo
channels.
Our targets are organized into several classes (Table 1A),
accessible through the website, each divided into families
and subfamilies (Figure 1). Classifications can overlap, for
example ‘Immune checkpoint proteins’ are in both the ‘Cat-
alytic receptor’ and the ‘Other protein target’ classes. Join-
ing these different target types is useful to immunologists,
given the proteins’ shared roles in regulating T cells and
macrophages.
Ligands. Criteria for including a ligand remain focused
on well-characterized, quantitative interactions with pro-
tein targets (Table 1B). Of the 816 ligands tagged as hav-
ing relevance to immunopharmacology (see GtoImmuPdb
Expansion-‘Content and curation’ section for details),
∼30% have been added since the last update. As previ-
ously, ligands without an experimentally-verified molec-
ular mechanism of action, but where potential efficacy
is clearly described in papers, are also captured. There
are new ligand groups, for example Immune check-
point modulators (www.guidetopharmacology.org/GRAC/
FamilyDisplayForward?familyId=969), which group dis-
parate ligands with common functionality. We have ex-
tended the database schema to group some ligands into
families using the information on Hugo Gene Nomen-
clature Committee (HGNC) gene family pages (www.
genenames.org/cgi-bin/genefamilies/) (15,16); examples in-
clude cytokines and chemokines. A new family listing page
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Figure 1. The hierarchical listing for the catalytic receptor families and subfamilies. (A) Shows the GtoPdb view and (B) shows it with the Guide to
IMMUNOPHARMACOLOGY (GtoImmuPdb) view switched on, which highlights families containing targets of immunological relevance. A toggle
button enables switching between GtoPdb and GtoImmuPdb views, the only difference being that the GtoPdb view does not have highlighting.
exists under the ‘Ligands’ sub menu of the main nav-
igation bar and also from the ligand list and individ-
ual ligand pages (www.guidetopharmacology.org/GRAC/
LigandFamiliesForward).
Interactions and database growth. Table 1C and Figure 2
show the expansion of curated interaction data across tar-
gets and ligands.Most targets added over the past two years
fall into the ‘Enzyme’ and ‘Other protein’ target categories.
PubChem content. Our PubChem integration strat-
egy has been previously outlined (5). Since 2015 we
have made nine PubChem submissions for new re-
leases of our database. For 2017.5 (see release notes
https://blog.guidetopharmacology.org/2017/08/22/
database-release-2017-5/) we now have 8978 Substance
Identifiers (SIDs) (PubChem query ‘IUPHAR/BPS Guide
to PHARMACOLOGY’[SourceName]). We submit within
days of our public release but it can take PubChem a few
days to process a new submission and several weeks to
complete the more computationally intensive relationship
mappings (e.g. 3D neighbours).
Figure 3 shows an analysis of our content in Pub-
Chem. For the SIDs (Figure 3A), we have extended our
SID comments to be able to identify ‘approved drug’
and ‘immunopharmacology’ subsets. Submission to Pub-
Chem allows users the useful ability to compare differ-
ent sources, using filters for ‘slicing and dicing’ (17). Do-
ing so highlights our complementarity to other sources,
such as GtoPdb having 1595 CID structures that ChEMBL
does not (Figure 3B). The same figure shows that in
the case of both DrugBank (18) and DrugCentral (19)
there are ∼5500 CIDs unique to just GtoPdb. A more
detailed discussion of GtoPdb PubChem content and
comparisons to other chemical sources can be found in
our blog (https://blog.guidetopharmacology.org/2017/10/
18/gtopdb-nar-database-issue-2018-pubchem-content/).
Website enhancements
BLAST. We have extended the GtoPdb query tools with
BLAST (20) sequence-based searching of targets (www.
guidetopharmacology.org/blast/), bypassing ambiguities of
protein names. Users can BLAST a query sequence against
GtoPdb targets either using a polypeptide or a nucleotide
sequence, which will be automatically translated in all pos-
sible frames before querying. There is the option of supply-
ing either FASTA sequences or plain-text sequences, pasted
directly into the search box or uploaded. There are various
controls to filter by species, number of hits and maximum
Expect value (E).
SAR data. To facilitate SAR studies with ligand sets for
individual targets we have added the ability to download
SAR data in comma-separated values (CSV) format. A
link to an SAR file has been added to every target page
above the tables of ligand binding data. To access SAR
data for all targets, we point users to our download page
(www.guidetopharmacology.org/download.jsp) where they
can download a CSV file containing all interactions.
Visualising ligand activity across species. Many phar-
macological parameters are reported in results sections
of papers and cannot easily be found by searching
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Table 1. Guide to PHARMACOLOGY database counts for targets, ligands and interactions from database release 2017.5
GtoPdb 2016 GtoPdb 2018 (±2016) GtoImmuPdb 2018
A. Target class content. Human UniProtKB accession counts
7TM receptors* 395 395 (0) 86
Nuclear hormone receptors 48 48 (0) 6
Catalytic receptors 239 243 (+4) 107
Ligand-gated ion channels 84 81 (-3) 3
Voltage-gated ion channels 141 144 (+3) 17
Other ion channels 47 49 (+2) 0
Transporters 508 509 (+1) 5
Enzymes (all) 1164 1184 (+20) 134
Kinases 539 546 (+7) 79
Proteases 240 243 (+3) 32
Other proteins 135 174 (+39) 64
Total number of targets 2761 2834 (+73) 420**
B. Ligand category counts
Synthetic organics 5055 5807 (+752) 449
Metabolites 582 584 (+2) 23
Endogenous peptides 759 782 (+23) 176
Other peptides including synthetic peptides 1222 1297 (+75) 37
Natural products 234 247 (+13) 9
Antibodies 138 223 (+85) 121
Inorganics 34 38 (+4) 1
Approved drugs 1233 1334 (+101) 208
Withdrawn drugs 67 67 (0) 11
Ligands with INNs 1882 2114 (+232) 336
PubChem CIDs 6037 6702 (+665) 484
PubChem SIDs 8024 8978 (+954) 816
Total number of ligands 8024 8978 (+954) 816
C. Interaction counts
Human targets with ligand interactions 1505 1684 (+179) 390
Human targets with quantitative ligand interactions 1228 1431 (+203) 321
Human targets with approved drug interactions 554 563 (+9) 152
Primary targets*** with approved drug interactions 312 313 (+1) 91
Ligands with target interactions 6796 7663 (+867) 718
Ligands with quantitative interactions (approved drugs) 5860 6716 (+856) 553
738 824 (+86) 138
Ligands with clinical use summaries (approved drugs) 1724 2089 (+365) 423
1231 1332 (+101) 208
Number of binding constants 44 691 46 488 (+1797) 23 304
Number of binding constants curated from the literature 13 484 15 281 (+1797) 10 964
References 27 880 31 733 (+3933)
* Not all the 7TM receptor records are unequivocally assigned as GPCRs, but for convenience we refer to these generally as GPCRs in the text.
** Thirty-five targets are tagged in GtoImmuPdb but have no Human UniProtKB accession. Thirty-four of these are complexes (only subunits have
UniProtKB accessions, and 1 that only has a mouse accession).
*** Primary target indicates the dominant Molecular Mechanism of Action (MMOA)
**** An interaction is only considered part of GtoImmuPdb where both the target and ligand are tagged as relevant to immunopharmacology. The table
shows just under one quarter of all the curated interactions in GtoPdb involve targets and ligands of immunological relevance (we are still in the process
of identifying these so it is likely to increase).
The table includes a comparison to the figures from the 2016 update (5), and a breakdown for the GtoImmuPdb dataset. Categories are not mutually
exclusive and targets and ligands can fall into more than one, therefore totals are not the sum of all other rows.
of PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) ab-
stracts. Curated databases such as GtoPdb and ChEMBL
(21) extract these parameters into a database format which
facilitates findability and re-use. We have introduced inter-
active charts to summarize ligand activity at targets and
compare pharmacological parameters across species. The
bioactivity visualization tool uses data from GtoPdb and
ChEMBL to present box plots summarising reported activ-
ities for a ligand at different targets. The charts show various
pharmacological parameters expressed as -log10. For func-
tional assays, potency values may include pIC50 or pEC50
values of agonists; pA2 or pKB values for antagonists. For
ligand binding assays, values may be reported as pKd, pKi
or pIC50. Pharmacological parameters are defined in NC-
IUPHAR’s terms and symbols publication (22). The plots
for each species are given a unique colour, which allows
species differences to be quickly visualized (Figure 4).
Further information on assay details, references,
PubMed links and source databases are in tables below the
graphs. GtoPdb ligand binding data are supplemented with
additional values from ChEMBL (currently version 23,
updated when a new ChEMBL version is released) because,
while GtoPdb primarily focuses on human targets with
some supporting rodent data, ChEMBL covers a wider
range of species reported in medicinal chemistry literature.
Before including data from ChEMBL we applied filters,
ensuring only single protein targets or protein complexes
were included, normalising disparate pharmacological
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Figure 2. Human interaction data growth since 2013. The first (left-most) chart shows the number of human targets with curated ligand interactions while
the second chart includes only those targets that are supported by quantitative data. The third chart shows the number of target data-supported interactions
to approved drugs and the fourth chart shows primary targets of those drugs.
parameters to one of the five activity types above, con-
verting raw data to -log10 values, and ignoring assays not
marked as binding (B) or functional (F), as well as large
scale screening data and anything with the ‘outside typical
range’ warning flag.
NC-IUPHAR and GtoPdb faculty pages. NC-IUPHAR
subcommittees reviewing GtoPdb data have, over 14 years,
recorded contributions from over 800 scientists. To recog-
nize their invaluable contributions, we have added contrib-
utor faculty pages, with individual profiles listing details
of subcommittee membership and database contributions,
institutional address, ORCIDs and external profile links
such as departmental home pages, reference lists and so-
cial network profiles. The information is all entirely op-
tional and provided by the individual, so some profiles are
more complete than others. Contributor profiles may be
accessed by clicking on a contributor’s name in citations,
on the contributor list (www.guidetopharmacology.org/
GRAC/ContributorListForward) or via a database search.
The new faculty pages also provide users with greater in-
sight into the data review process and roles of subcommit-
tees.
GUIDE TO IMMUNOPHARMACOLOGY
The Guide to IMMUNOPHARMACOLOGY
(GtoImmuPdb) expansion has extended the database
to incorporate data types relevant to immunopharmacol-
ogy, and associate these with existing target and ligand
entities. This enrichment includes data on immunological
processes or pathways, cell types of relevance to immunol-
ogy, and diseases related to the immune/inflammatory
system. We have already described the new targets and
ligands included as part of GtoImmuPdb. Here we describe
methodology of tagging new and existing targets and
ligands along with the major data type expansions.
Content and curation
The immunopharmacology extension necessitated adapta-
tion of the selection criteria. We have been supported in
identifying key papers by new NC-IUPHAR committees,
and we expect to gather further feedback from users on the
papers they would like to include and/or remove.
Twitter is useful both for following a range
of immunology journals and for broader alert-
ing services such ImmuneRegulationNews (https:
//twitter.com/Immune News), Human Immunology News
(www.humanimmunologynews.com) and the British Soci-
ety for Immunology (https://twitter.com/britsocimm). We
have introduced an open pre-curation and contextual doc-
ument triage using ‘social tagging’ via CiteUlike (23). The
current list of over 700 immunopharmacology papers can
be browsed via http://www.citeulike.org/tag/immpharm.
These have an approximately equal split between context
papers (target reviews and mechanistic immunology, e.g.
(http://www.citeulike.org/user/efaccenda/article/14420478))
and those specifically designated for subsequent
curatorial extraction. The former are collated un-
der an immunopharmacology further reading page
(http://www.guidetoimmunopharmacology.org/GRAC/
ImmunoFurtherReadingForward). For the latter, pre-
curation notes are added in the comments section (e.g.
http://www.citeulike.org/user/cdsouthan/article/14414220),
with links to the database added post-curation. The ‘cura-
tion queue’ can be viewed at (http://www.citeulike.org/user/
cdsouthan/tag/tobecurated).
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Figure 3. Category breakdown at the SID (A) and CID (B) level for GtoPdb PubChem entries. Note, in panel A, that the intersect between approved drug
and immunopharmacology is derived from our curation of publications suggesting the association, but are not necessarily approved for immunological
clinical indications.
In setting up GtoImmuPdb we had many detailed cura-
torial aspects to consider but four are especially important.
The first is that there are no unique ligand or target enti-
ties since these are all subsumed into GtoPdb (and counted
in our statistics sections). This is a pragmatic consequence
of immunopharmacology being a subset of pharmacology.
The second is that we have made greater use of both the
Gene Ontology (GO) (24,25) (www.geneontology.org) and
the Cell Ontology (CO) (26) (http://obofoundry/ontology/
cl.html) for classifying targets. The third is we have intro-
duced new levels of disease linking, including associating
ligands directly to diseases for the first time. The fourth
is that since some existing targets are multi-purpose, we
needed to maintain a clear distinction between potential
GtoImmuPdb targets (e.g. identified based on GO annota-
tions and/or speculative comments in reviews) and those
where the papers we curated have made an explicit experi-
mental link in the form of ligands tested in systems relevant
to the declared goal of advancing to a therapeutic applica-
tion in immunology or inflammation. The necessity for this
division is particularly important for kinases in immune sys-
tem cells that can be targeted for cancer (e.g. antiprolifera-
tive) as well as immune system modulation.
Identifying targets and ligands of relevance to immunophar-
macology in GtoPdb
The initial step was to identify within GtoPdb all targets
and ligands relevant to immunopharmacology. We intro-
duced a new GtoImmuPdb tag for targets and ligands, and
added free-text comments describing reasons for inclusion
and information about the role the target or ligand plays
in immunopharmacology. Although the initial process used
an automatic pipeline (see below) to identify relevant enti-
ties, all the data were reviewed by curators (supported by
the appropriate committees or collaborators) before being
included in GtoImmuPdb.
The review process focused on three main rationales:
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Figure 4. Ligand activity chart for palosuran (ACT-058362, GtoPdb ligand ID 3516), a small molecule urotensin II receptor antagonist. Hovering the
mouse over the chart on a datapoint gives the median and range if more than one value is reported for the parameters shown on the horizontal axis. Zero
indicates no data are available for that parameter. In the example, the results show the IC50 value for palosuran inhibition of binding was about∼5000-fold
lower in rats compared with humans, showing a major difference between the two species.
i) Known immune related targets and ligands (e.g. his-
tamine receptors/antihistamine drugs, glucocorticoid
receptor/corticosteroid drugs, protein kinases and
their inhibitors used for immunology/inflammatory
indications, targets of approved monoclonals and other
biologics for immunology/inflammatory/immune-
oncology indications).
ii) Advice from our collaborators, who suggested several
targets on which to focus as proof-of-concept (e.g.
Bruton tyrosine kinase/Ibrutinib and other inhibitors,
colony stimulating factor 1 receptor and associated
pharmacological agents, Janus kinases and associated
pharmacological agents).
iii) Using GO annotations and literature reviews to priori-
tize immunological targets for curation (see below).
The counts of GtoImmuPdb tagged targets and lig-
ands are shown in Table 1, with the full list provided on
the website (http://www.guidetoimmunopharmacology.org/
immuno/immunoHelpPage.jsp#downloads).
Curators continually review literature covering immunol-
ogy and inflammation using the triage methodology de-
scribed above. New targets and ligands are added to
the database as new evidence emerges. We also review
clinical developments in immunity/inflammation/immuno-
oncology fields. This includes evaluating clinical develop-
ment pipelines, identifying lead compounds, their molecu-
lar targets and pharmacological data (which can involve in-
terrogation of patent literature where peer reviewed disclo-
sure is not yet available).
Incorporating immunological process data
The first step was to determine, in consultation with im-
munologists, the major processes relevant to immunology.
These top-level categories form the basis of organising, nav-
igating and searching for immunological process data (Ta-
ble 2). Existing targets in GtoPdb were then organized un-
der the relevant process categories.
The top-level process categories are underpinned by as-
sociating sets of GO immune and inflammatory biological
process terms (27) to each category. This serves two func-
tions; it gives a controlled vocabulary and external iden-
tifiers which support data interoperability, and enabled an
initial auto-curation of targets to the top-level process cat-
egories by using their GO annotations to classify them.
Relevant parent GO terms, and all their child terms, were
mapped to each category. This is illustrated in Figure 5
which shows the parent GO terms (and counts of child
terms) mapped to the T cell activation process category.
GO terms and IDs related to immune and inflamma-
tory processes were obtained from the GO Consortium
(http://purl.obolibrary.org/obo/go.obo) and used to popu-
late database tables. We captured all is a relationships be-
tween the terms to support inferred searching by GO terms.
This means a search on a parent term will also include any
of its children.
Target-GO annotations were downloaded from UniPro-
tKB (2017 08 release) (28) and parsed into the database,
along with GO evidence codes (www.geneontology.org/
page/guide-go-evidence-codes). GO evidence code indicate
the level of support for annotations to terms, which allows
users and curators to judge the strength of the evidence for
the association. Associations where the evidence is tenuous,
such as for the IEA (Inferred by Electronic Analysis) code,
can be split (this is the only evidence code that is assigned
automatically by GO, without curatorial judgement).
The set of target-GO annotations was used to auto-
matically assign targets to the top-level categories. Our
curators then reviewed the annotations. Table 2 summa-
rizes the total number of GO annotations to targets, and
the number of UniProtKB proteins, under each category.
These mappings can be downloaded from the website
(http://www.guidetoimmunopharmacology.org/immuno/
immunoHelpPage.jsp#downloads). All process associa-
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Table 2. GtoImmuPdb process category with count of human UniProtKB proteins assigned to them based on GO annotations
Process category GtoPdb human UniProtKB Target-GO annotations
Barrier integrity 40 52
Inflammation 576 1277
Antigen presentation 158 226
T cell (activation) 172 345
B cell (activation) 136 222
Immune regulation 435 1072
Tissue repair 18 18
Immune system development 199 350
Cytokine production and signalling 390 979
Chemotaxis and migration 229 382
Cellular signalling 448 1079
Figure 5. Illustrating the mapping of GO parent terms to the GtoImmuPdb top-level process category, T-cell activation. Six parent terms are mapped,
which encompasses 471 distinct child terms. Using GO annotations to UniProt we find that there are 172 human targets in GtoPdb with annotations to
one or more of those 471 GO terms (see Table 2).
tions can be browsed from the Immuno Process association
pages (www.guidetoimmunopharmacology.org/GRAC/
ProcessesForward). In order to keep GO annotations
up-to-date with the latest UniProtKB release, we have
semi-automated scripts that are run upon each database
release.
Incorporating immune system cell type data
We used a similar approach to incorporate cell type data.
We sought input from immunologists to establish a set
of top-level cell type categories, against which targets in
GtoImmuPdb can be annotated. For example mast cells
are included due to their relevance in anti-allergic therapies
(29), and there is a category for innate lymphoid cells, re-
flecting the growing understanding of their role within the
innate immune system in the control of tissue homeostasis,
infection, inflammation, metabolic disease and cancer (30).
We have under-pinned these categories with terms from the
CO. The full list of cell type categories, their CO term as-
signments, and a breakdown of targets in each category are
given in Table 3.
The top-level categories broadly correlate with the CO
terminology. We then selected relevant parent terms and
mapped these to our top-level categories. This enables
inferred searches to be run via any CO term, finding
targets associated to that term or its children. It also
supports higher resolution annotation and gives a con-
trolled vocabulary and external identifiers. Cell type as-
sociations can be browsed from the Immuno Cell Type
association pages (www.guidetoimmunopharmacology.org/
GRAC/CelltypesForward).
Associating diseases on immunological relevance
GtoPdb already contained data on diseases, including
clinically-relevant mutations and pathophysiological roles
of targets. We have extended the schema to include specific
associations of targets and ligandswith diseases of immuno-
logical relevance. Curatorial comments describe the link be-
tween the target or ligand and the disease, along with sup-
porting literature references. New disease summary pages
link information on approved drugs, clinical use and pri-
mary targets to disease associations, bringing new perspec-
tives to immunopharmacology data.
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Table 3. GtoImmuPdb cell type top-level categories, with associated Cell Ontology terms and count of distinct targets annotated to each category
Cell type category Cell Ontology terms Targets annotated
B cells CL:0000945 lymphocyte of B lineage 32
T cells CL:0000789 alpha-beta T cell 39
CL:0000815 regulatory T cell
CL:0000911 effector T cell
Dendritic cells CL:0000451 dendritic cell 29
Other T cells CL:0000798 gamma-delta T cell 1
CL:0000814 mature NK T cell
CL:0000898 naive T cell
CL:0000940 mucosal invariant T cell
Macrophages and monocytes CL:0000235 macrophage 37
CL:0000576 monocyte 37
Granulocytes CL:0000094 granulocyte 34
Natural killer cells CL:0000623 natural killer cell 21
Mast cells CL:0000097 mast cell 26
Innate lymphoid cells CL:0001065 innate lymphoid cell 0
Stromal cells CL:0000499 stromal cell 0
T cells are split into two categories, ‘T cells’ and ‘other T cells’, which was to keep the regulatory T cells together and distinct from other T cell types.
We consulted several resources––OMIM (31) (www.
omim.org/), Orphanet (www.orpha.net) and the Disease
Ontology (32) (http://disease-ontology.org/). Incorporating
their disease terminology provides a controlled vocabulary,
and cross-references our disease associations to other re-
sources.
The GtoPdb database contains over 2000 disease terms
(including synonyms). We have so far matched over 300
to ligands of immunological relevance. Curation of targets
against immunological disease is in its infancy, but already
contains associations to 17 immunological diseases. As ex-
pected, these include those under particularly active inves-
tigation (as judged by the current literature output), such
as asthma, rheumatoid arthritis, inflammatory bowel dis-
ease, chronic obstructive pulmonary disease, sepsis and fi-
brosis. A full breakdown of the disease associations can be
viewed at www.guidetoimmunopharmacology.org/GRAC/
ImmunoDiseaseListForward?type=target.
WEBSITE
The GtoPdb website has been extended to surface new data
types and incorporate them into existing search and browse
mechanisms. We have not developed a new resource, but
have extended the existing database and website with a new
‘layer’ of immunological data and an interface for immu-
nologist users, the ‘GtoImmuPdb view’ of the data. This
view highlights content of immunological relevance and
prioritizes immunological data in search results and dis-
plays. In addition, we created a new entry portal (at www.
guidetoimmunopharmacology.org) which provides access
points to immunological data.
At this stage, the Guide to IMMUNOPHARMACOL-
OGY is in beta-release (v2.0): although it contains most
features and functionality expected in the full public release
(due in 2018), it remains under development and may con-
tainminor bugs and/or portions not yet optimized. Full de-
tails on navigating the new features of GtoImmuPdb are in
our website tutorial (www.guidetoimmunopharmacology.
org/immuno/docs/GtoImmuPdb Tutorial.pdf).
Portal
The GtoImmuPdb portal is intended to provide a new ac-
cess point to the database, with quick access to the data
types of most relevance to immunopharmacology. The por-
tal is styled after its parent GtoPdb, but with its own dis-
tinctive logo, header and colour scheme. This ensures that
it is intuitively familiar to GtoPdb users while at the same
time maintaining its own identity. We have also used the
new colour scheme to highlight content of relevance to im-
munopharmacology within the existing GtoPdb interface.
In several places toggle buttons allow users to switch be-
tween the new GtoImmuPdb view and the existing GtoPdb
view (see Figure 1). The portal provides easy access to
the new data types via panels on the portal home page.
Detailed descriptions of navigating and viewing data in
GtoImmuPdb are given in the next few sections. A revised
menu bar has been developed for GtoImmuPdb that in-
cludes links and resources specific for GtoImmuPdb, in-
cluding links to the new Process, Cell Type and Disease
data. The site-wide search box in the top-right has also
been modified to search across the new data types (see the
‘Searching GtoImmuPdb’ section for details).
Process associations to targets
Clicking one of the top-level categories on the Processes
panel displays a new page listing all targets associated
with that process (www.guidetoimmunopharmacology.org/
GRAC/ObjectImmProcessListForward?immprocess=2).
For each target, curators’ comments give detailed infor-
mation about the target’s relevance to the immunological
process and immunopharmacology in general. Immune-
relevant GO annotations to the targets, including the GO
ID and evidence code, are displayed, enabling users to
assess the strength of the association. Targets are orga-
nized into sections, one for each main target class; quick
links at the top of the page allow users to jump to each
of these sections. The page also has a pull-down menu
containing all the top-level process categories, enabling
the user to easily switch between different categories. The
process associations to target pages can also be accessed
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via the main menu bar and there is a processes home
page (www.guidetoimmunopharmacology.org/GRAC/
ProcessesForward) that summarizes each of the categories,
including lists of the GO parent terms that are used to
define them.
Cell type associations to targets
Users can click on the portal’s cell types panel
to access a list of targets associated to each cell
type (www.guidetoimmunopharmacology.org/GRAC/
ObjectCelltypeAssocListForward?immcelltype=2) (Figure
6A). This is very similar to the process list described
above. Curators’ comments are displayed next to CO terms
and IDs for each target. It includes links to each target
class, and a pull-down menu to switch between cell type
categories.
Disease associations
The portal also links to lists of curated immunological dis-
ease associations to either targets or ligands. Figure 6B
shows the display for ligands associated to immunological
diseases. Users can switch between viewing targets or lig-
ands via a tab at the top of the page. Diseases are listed in
alphabetical order, with external references to OMIM, Or-
phanet and the Disease Ontology.
A single disease may be associated with many different
ligands, although usually not as many targets. Therefore,
the page keeps the full list of targets and ligands associated
with each disease hidden on initial view. The total number
of targets or ligands associated with the disease is shown,
along with a preview of the names of the first few targets
or ligands. A toggle link can be clicked to expand the sec-
tion to list all associations. There are controls on the page
to hide or show all the disease associations if required. In
the expanded view, target associations show the name of the
target, curator comments and lists of approved drugs (lig-
ands which are currently, or have been in the past, approved
for human clinical use by a regulatory agency) that interact
with the target. This list is restricted to only those drugs for
which the target is classed as a primary target of the com-
pound. When viewing disease associations to ligands in the
expanded view, it lists the ligand name (linked to the ligand
summary page) and curator comments.
Targets
Targets are browsed in GtoPdb via hierarchical trees
of protein families. This display has been enhanced for
GtoImmuPdb by highlighting families of immunological
relevance in blue (Figure 1B). Likewise, when viewing a
family page, any individual targets of immunological rele-
vance are also highlighted. New toggle buttons allow users
to switch between GtoPdb and GtoImmuPdb views. The
detailed view page for a target has been extended to in-
clude the new immunological data types incorporated for
GtoImmuPdb. The same data are displayed in both views,
but in the GtoImmuPdb view the new sections are high-
lighted, helping to alert users to the content. These include
general comments on immunopharmacology as well as any
process, cell type or disease associations (Figure 7 A and
B). Additionally, within the existing sections of the detailed
view page that list ligand interactions, a new GtoImmuPdb
logo is displayed where the ligand has been tagged of rele-
vance to immunopharmacology (Figure 7C).
Ligands
Modifications have been made to the way ligand categories
are displayed under GtoImmuPdb. The ligands panel on
the portal prioritizes the immuno ligand and antibody cat-
egories (likely to be of greater interest to immunologists).
When viewing the ligand list page, a new ‘immuno’ ligands
category has been added as a tab andwhen viewing any cate-
gory under the GtoImmuPdb view, only ligands tagged (see
‘Content and curation’ section) in GtoImmuPdb are dis-
played. Again, a toggle allows the user to switch between
GtoPdb and GtoImmuPdb views. As on target pages, rel-
evant ligands are highlighted using the new immunophar-
macology icon. Individual ligand summary pages also now
have a tab that includes immunopharmacology-related data
specific to the ligand. At present, this includes curator com-
ments, disease associations and references.
Searching GtoImmuPdb
Search mechanisms have been extended to incorporate all
additional immunological data, including process, cell type
and disease terms, ontological definitions and ontology IDs.
We have also modified the search algorithm when search-
ing via the GtoImmuPdb portal to increase the ranking of
results likely to be of greater immunological relevance. We
applied a weighting to certain database fields so that entities
matching on those fields will appear higher up the list of re-
sults. The weighting is only applied when searching from a
GtoImmuPdb page, not from the standard GtoPdb pages
and is based on the amount of immunological data curated
against an entity. For example, targets that have process,
cell type and disease data annotated against them will rank
higher than targets with only process data. This is in addi-
tion to existing search weightings––so exactmatches (to tar-
get or ligand name for example) will still get a higher score.
Help and tutorials
We encourage users to familiarize themselves with the new
data and navigation of the GtoImmuPdb portal by brows-
ing the help pages (www.guidetoimmunopharmacology.
org/immuno/immunoHelpPage.jsp) and the specific tu-
torial (www.guidetoimmunopharmacology.org/immuno/
docs/GtoImmuPdb Tutorial.pdf). The help pages also
contain links to download sets of GtoImmuPdb data. We
have also added popup help guides on the main portal for
each major data type.
COLLABORATIONS, CONNECTIVITY AND INTEROP-
ERABILITY
ELIXIR
ELIXIR is the European infrastructure established specif-
ically for the sharing and sustainability of life science
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Figure 6. Displaying GtoImmuPdb data. (A) Shows the display of GtoImmuPdb cell type to target associations, here showing T cells. This layout is also
used for the display of process association data. (B) Shows the display of ligand disease associations, showing the first three ligands for rheumatoid arthritis.
data (www.elixir-europe.org/). The UK node, ELIXIR-UK
(www.elixir-uk.org/), expanded in 2015/16, sought to iden-
tify resources that were representative of the UK bioinfor-
matics community (33) and bring the benefit of participa-
tion to a wider range of UK institutions. Falling within
ELIXR’s strategic theme of human health and disease,
GtoPdb already has links with other ELIXIR resources,
including UniProtKB (where we regularly update cross-
references), and is in a good position to interoperate with
other resources through our use of standard ontologies and
identifiers (UniProtKB Accessions, nomenclature (as as-
signed by NC-IUPHAR committees in collaboration with
HGNC), Ensembl IDs, PubMed IDs and PDB IDs).We see
to improve our interoperability and FAIR (Findable, Acces-
sible, Interoperable, Reusable) compliance (34) by produc-
ing GtoPdb in Resource Description Framework (RDF)
format, thereby making the data and the ontologies used
machine readable.
RDF
Over the last year, work has been carried out to design
and implement an RDF version of a subset of the GtoPdb
dataset, now available from (www.guidetopharmacology.
org/downloads.jsp). The RDF data generation has been fo-
cussed on the main target–ligand interaction data. To en-
sure FAIR compliance machine-readable metadata have
been generated in accordance with the W3C Health Care
and Life Sciences Community (HCLS) Profile (35). As an
example ofRDFmodelling, the interaction between the tar-
get 5-HT1A receptor and the ligand Ipsapirone is shown in
Figure 8. In addition to the already stated aim of making
GtoPdb FAIR compliant, it was also planned as a way to
include theGtoPdb data into theOpen PHACTSDrugDis-
covery Platform (36,37).
We have developed an ontology (http://rdf.
guidetopharmacology.org/ns/gtpo), that represents the
schema of the RDF data, in accordance with current best
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Figure 7. Showing the target detailed view page with immunological data highlighted. (A) Top section of the detailed view page for RIG-1 (DExD/H-Box
helicase 58) with immunopharmacology content links highlighted. (B) Immunopharmacology data sections on the detailed view page. (C) Ligand binding
data (from Bruton tyrosine kinase) showing the new immunological icon in blue to highlight ligands also tagged in GtoImmuPdb.
Figure 8. Schematic diagram illustrating the RDF relationship between the target 5-HT1A receptor and the ligand Ipsapirone.
practice (38) using the ‘Indirect reuse of ontology design
patterns and alignments’ ontology design pattern (39).
The units used for the affinity values in the interactions
are reused from the BioAssay Ontology (BAO) (40).
Working with the maintainers of BAO new entries have
been added for pKB, pKi and pKd. Defining our own
core ontology allowed us to: (i) ensure that the terms
capture the actual interpretation in GtoPdb – the terms
were modelled around the existing GtoPdb glossary (http:
//www.guidetopharmacology.org/helpPage.jsp#glossary);
(ii) eliminate potentially unstable external dependencies.
The downside of the approach is that the terms are not
immediately interoperable, for example with the ChEMBL
terms, except via the use of the equivalence mappings that
are published alongside the ontology. The RDF data are
generated from the corresponding released version of the
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GtoPdb database. This ensures that the RDF data are
consistent with the database content and do not require
the maintenance of a second database. Three relational-
to-RDF (R2RM, (41)) mapping files have been created
that control the generation of the RDF data––one each
for targets, ligands and interactions respectively. These
are available from https://github.com/HW-SWeL/GTP-
RDF/tree/master/Morph/Guide2Pharma/R2RML. We
execute the mappings using the Morph RDB framework
(42). Again, following best practice (43), a table identifier
scheme has been established for the RDF data. Another key
aspect of the generation process is the creation of machine-
readable metadata. The metadata capture the provenance
information between the RDF version of the data and the
relational database version that was used to create it. The
metadata comply with the W3C HCLS Community Profile
to the SHOULD level and this has been verified with the
Validata tool (http://hw-swel.github.io/Validata).
We are in the process of providing linked data pages for
each resource in the RDF data, i.e. the URL used to iden-
tify each target, ligand and interaction in the RDF will be-
come dereferenceable. Additionally, we will be providing a
SPARQL endpoint with a set of example queries to help
exploit the RDF data and enable deeper analysis of the
GtoPdb data in conjunctionwith other linked data datasets.
In the future, we will provide link-sets that capture the
database cross-references contained in the GtoPdb as well
as extend coverage of the data.
Database links
The current set of database link-outs from GtoPdb
target and ligand pages can be viewed at www.
guidetopharmacology.org/helpPage.jsp#databaseLinks.
New links since 2016 on the ligand side include UniChem,
which cross-references between chemical structure iden-
tifiers from different databases (44). On the target
side, there are links to the SLC Transporter Database
(http://slc.bioparadigms.org/) with information on trans-
porter functional genomics, CATH structural domains
and superfamilies (45) and the Human Protein Atlas tissue
expression database (46), these latter two being ELIXIR
core resources (47). We have also ensured cross-links exist
betweenGtoPdb and the Pharmacology EducationWebsite
(PEP, www.pharmacologyeducation.org/) and SynPharm
(http://synpharm.guidetopharmacology.org/), the database
of ligand-binding sequences.
We ensure that the cross-links are regularly refreshed
through formal and informal contacts with database
providers. Of note are the links to RCSB Protein Data
Bank (PDB) (www.rcsb.org) (48) ligands. The acceleration
at which pharmacological targets are being co-crystallized
with ligands caused us to introduce PDB InChIKey look-
ups as part of our database update procedure, to en-
sure that links are up-to-date in each release. Consequent
to the creation of peptide ligand family pages, we also
updated our reciprocal HGNC links to include human
genes encoding peptide ligands.We encourage in-links from
other resources, although it is difficult to discern the ex-
tent of these unless we are directly informed or cited. A
recent survey (https://blog.guidetopharmacology.org/2016/
03/30/collation-and-assessment-of-gtopdb-in-links) found
these were over 20 in number and we also not that we have
recently been incorporated into an internal-only resource,
the CHEMGENIE database from Merck & Co (49).
Journal to database connectivity
GtoPdb has continued to enhance its connectiv-
ity to journals. Much of our endeavours since our
last update (5) have been described in our blog
(https://blog.guidetopharmacology.org/2017/10/18/
gtopdb-nar-database-issue-2018-journal-to-database-
connectivity-and-journal-to-gtopdb-links/). This includes
details on PubMed ID statistics in curated GtoPdb content.
The same post also shows how engagement with British
Journal of Pharmacology (BJP) has extended the previous
provision of live out-links (50), to now include in line links,
rather than the previous method of adding separate tables
to manuscripts.
External profile
We use a number of strategies to disseminate information
about GtoPdb. Our NC-IUPHAR newsletter is prepared
in sync with database releases and sent to subscribers
and committee members with articles about the database
and hot topics in pharmacology. Social media (Twitter,
Facebook and LinkedIn) is one of our primary methods
of outreach to announce database updates, publications of
interest, upcoming events and IUPHAR reviews. Our blog
(https://blog.guidetopharmacology.org/) is used to provide
detailed descriptions of database releases, technical up-
dates and commentary on hot topics in pharmacology. For
example, the development of the Guide to IMUNOPHAR-
MACOLOGY is described in a series of technical blog
posts (https://blog.guidetopharmacology.org/category/
guide-to-immunopharmacology/). We also share posters
and presentations made by the team on our SlideShare
account (www.slideshare.net/GuidetoPHARM). We
track user interactions via Google analytics which shows
a monthly average of ∼29 500 sessions from 19 500
users, over the 6 months from April 2017 to Septem-
ber 2017. We have also produced our third edition of
The Concise Guide to PHARMACOLOGY 2017/18
that includes links to 1679 targets and 3524 ligands
(www.guidetopharmacology/concise).
FUTURE DIRECTIONS
Guide to IMMUNOPHARMACOLOGY is in its beta
phase: we expect the portal and website to be completed by
Spring 2018 when the first full public release will be avail-
able. At present, most features of the interface are in place.
We have undertaken a short phase of user-testing; an exer-
cise we plan to repeat before the full public release. This will
identify any aspects of the design and navigation that need
improvement, and features that users would like to see im-
plemented. In response to previous user feedback we will
also consider a graphical-based navigation system to im-
prove user-friendliness and enhance the look of the website.
New data curation will continue until Autumn 2018, with
a focus on target associations to disease and cell types that
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are currently under-represented in the database.Wewill also
continue to assign further targets to top-level immunolog-
ical process categories by looking at their GO annotations
and supporting evidence.
We will continue the development of our RDF platform
with short-term priorities of establishing a linked data ex-
plorer and a SPARQL end-point to enable queries across
the data. Making the RDF publicly available allows inte-
gration into other semantic databases (both proprietary and
non-proprietary).
We are alsoworkingwith Bioschemas (http://bioschemas.
org/) to add schema.org semantic mark-up to GtoPdb,
whichwouldmake it easier for search engines to find, collate
and analyse the data (51).
Many of the main use-cases and features in GtoPdb will
be elaborated on in a forthcoming paper in Current Proto-
cols in Bioinformatics (manuscript in preparation).
A new, sister resource to the main GtoPdb called Syn-
Pharm (http://synpharm.guidetopharmacology.org/) has
been developed as a database of drug-responsive protein se-
quences, derived from the interactions in GtoPdb and us-
ing data from the RCSB PDB. SynPharm is an open-access,
web-based tool that integrates pharmacological and ligand–
protein binding information to present data on the drug-
binding domains of proteins in a manner useful to synthetic
biologists. It will be kept up-to-date in line withGtoPdb and
we are preparing a paper detailing the resource.
DATA ACCESS
GtoPdb and GtoImmuPdb are available on-
line at http://www.guidetopharmacology.org and
http://www.guidetoimmunopharmacology.org, re-
spectively. Both are licensed under the Open
Data Commons Open Database License (ODbL)
(http://opendatacommons.org/licenses/odbl/), and
the contents are licensed under the Creative Com-
mons Attribution-ShareAlike 3.0 Unported license
(http://creativecommons.org/licenses/by-sa/3.0/). Recom-
mendations for accessing and downloading data, and
linking to us remain as reported in 2016. We provide
various options for download, and users are welcome to
contact us (enquiries@guidetopharmacology.org) for addi-
tional datasets and file formats. We provide a dump file of
the full PostgreSQL database (http://www.postgresql.org/)
but we no longer provide a MySQL version as standard
(although we would be glad to provide this on request).
We also provide RDF flat files as described above (avail-
able from www.guidetopharmacology.org/downloads.jsp),
which users can load into a local triple store and perform
SPARQL queries across the data. Our REST web services
are available at http://www.guidetopharmacology.org/
webServices.jsp and provide computational access to data
in JavaScript Object Notation (JSON) format. In response
to user feedback we recently expanded and revised our
web services and made speed improvements. We added
services to allow direct querying of interaction data and
references. For example, users can now obtain a complete
set of target–ligand interactions with many options to filter
this list, including by target or ligand type, binding affinity,
drug approval status or chemical structure. We encourage
users to get in touch if they download data in any format,
both for further advice and so we are aware of applications
using GtoPdb data.
CITING THE RESOURCE
Please cite this article rather than the previous ones; cita-
tion advice for specific target pages appears on the web-
site. Please refer to our resources on first mention by full
correct name (IUPHAR/BPS Guide to PHARMACOL-
OGY and IUPHARGuide to IMMUNOPHARMACOL-
OGY) including the capitalization. For subsequent abbre-
viation please use GtoPdb and GtoImmuPdb and spec-
ify the release version number (this can be found on our
About page (http://www.guidetopharmacology.org/about.
jsp#content)).
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